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INTRODUCTION
The CD37 antigen is a transmembrane protein of the tetraspanin superfamily that is highly expressed on B cells during the pre-B to peripheral mature B-cell stages, but is absent on early B progenitor cells or terminally differentiated plasma cells (1, 2) . It is weakly expressed in a subset of PBMCs and in tissues where lymphocytes reside/infiltrate (1) . Although the exact physiological role of CD37 is unclear, it has been implicated as a signaling death receptor (3) and observations from knockout mice suggest that it is not essential for B-cell development, but may function to regulate B/T-cell interactions/proliferation as well as aspects of humoral and cellular immune responses (4, 5) . With respect to cancer, CD37 is highly expressed on malignant B cells in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (6) .
Consequently, CD37 represents a promising therapeutic target for B-cell malignancies.
Anti-CD20 antibodies such as rituximab, ofatumumab and obinutuzamab have proven to be effective for the treatment of NHL and CLL, either as single agents or in combination therapy (7, 8) . The intrinsic anti-cancer activities of these antibodies include direct signaling/pro-apoptotic activity, ADCC and CDC. However, many patients eventually relapse or experience resistance to available treatments, creating a need for additional therapeutic options. The clinical experience with CD37 targeted agents is still in its infancy and is as follows CD37 antibody component with the cytotoxic potency of its DM1 maytansinoid payload, is also in development (13) .
Encouraged by the clinical successes of ADCETRIS® (brentuximab vedotin) (14) and KADCYLA® (ado-trastuzumab emtansine) (15) , the currently approved ADCs targeting cancer, we have developed AGS67E, a fully human anti-CD37 IgG2 antibody conjugated to the potent microtubule-disrupting agent, MMAE, via reduced cysteines and the protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. Unlike all other reported therapeutic CD37 antibodies, including the recently reported IMGN-529 ADC (13), the unconjugated antibody component of our ADC does not exhibit intrinsic apoptotic or ADCC activity. The activity of AGS67E derives from its MMAE payload which is selectively delivered by a highly specific antibody (AGS67C). Once delivered, AGS67E induces apoptosis, cell cycle alterations and cytotoxicity in vitro as well as anti-tumor efficacy in vivo. Since the pre-clinical potency of our agent is similar or superior to the reported pre-clinical efficacy of other CD37
antibodies in similar models of B cell malignancies (11-13), we postulated that adding ADCC and apoptosis inducing capabilities to our unconjugated antibody was unnecessary and further that it could prove to be a liability from a toxicology or PK perspective.
Aside from a novel CD37 ADC that we report here, we also report for the first time, that CD37 is well expressed in T-cell lymphomas and AML and that AGS67E exhibits potent anti-tumor efficacy in pre-clinical models of AML including patient-derived models. Moreover, we show that CD37 is differentially expressed in CD34+CD38-AML versus normal stem cells.
Taken together, our findings suggest that AGS67E may serve as a potential therapeutic for B/Tcell malignancies as well as AML. To our knowledge, this body of work is the first demonstrating that CD37 is well expressed and a potential drug target in AML.
MATERIALS AND METHODS
Immunohistochemistry:
Immunohistochemistry (IHC) was used to evaluate CD37 expression in human lymphoma microarray samples (US Biomax) of formalin-fixed and paraffin-embedded (FFPE) tissue sections. Briefly, FFPE sections were de-paraffinized, re-hydrated, treated for antigen retrieval, and incubated with VCD37-9a73.1 (1 μg/mL), an in-house developed mouse anti-CD37 antibody or control IgG (1 μg/mL). Immunoreactivity was detected using a Super Sensitive Polymer-HRP IHC Detection Kit (Biogenex Laboratories). Positivity was calculated by summing the percentage of tumor cells stained at a given staining intensity (0=negative, 1=weak, 2=moderate, 3=strong) multiplied by the weighted intensity to yield: high (201-300); moderate (101-200); low (1-100); and negative (0) H-scores.
Antibody Generation, Purification and Conjugation:
Anti-CD37 antibodies were generated using standard hybridoma technology in genetically engineered VelocImmune TM mice humanized for the Ig locus (Regeneron Pharmaceuticals, Inc) (16) . The immunogen was 293T cells overexpressing human CD37. Following hybridoma screening, v67-6b15 was selected as the lead hybridoma from a fusion that yielded a total of 34 positives. It is cross-reactive to cynomolgus monkey but not rodent CD37. To create a fully human antibody, total RNA was extracted from the antibody producing hybridoma cells using Trizol Reagent (Life Technologies) and the manufacturer's suggested protocol. cDNA synthesis was generated from total RNA using RACE cDNA Amplification kit (Clontech) and a reverse primer within the constant region of the human light and heavy chains according to the manufacturer's protocol. The amplified variable human heavy and kappa light chains were sequenced and cloned into a mammalian cell expression vector encoding human IgG2 and kappa constant domains. The plasmid was transfected into CHOK1SV host cells (Lonza) to generate stable antibody (AGS67C) producing cell line. AGS67C was purified from conditioned CHO supernatant loaded onto a Protein A sepharose column. The antibody was eluted in 0.1M Glycine, pH 3.5 and neutralized using 2M Tris, pH 9.0. To create AGS67E, AGS67C was conjugated with MMAE, linked to reduced cysteines of the antibody via a protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamoyl as previously described (17) .
The drug antibody ratio was 3.7. Once conjugated, AGS67E was purified from the reaction mixture using PD10 desalting columns. 
Cell Lines:
Exponentially growing cell lines were harvested, reconstituted and incubated for 1 hr on ice with biotinylated AGS67C and isotype control. Following a wash, R-PE-Streptavidin was incubated for 1 hour, washed and cells were analyzed on an Attune Acoustic Focusing Cytometer (Life Technologies). Data files were analyzed using FlowJo 7.6.5 software using standard gating. 
AGS67E in vitro Cytotoxicity:
Exponentially growing cells with a viability of 95% or greater were plated in fresh RPMI-1640 (Gibco-Invitrogen) media containing phenol red supplemented with 10% FBS (heat inactivated), 10 mM Hepes and 1mM Sodium Pyruvate. Cells were left overnight and treated with AGS67E
and an isotype control. After 5 days of treatment and incubation at 37°C and 5% CO 2 , cell viability was measured following a 1hr at 37°C incubation with Presto Blue Reagent (Invitrogen).
Samples were analyzed using a Synergy Microplate reader. Survival values were plotted using Graph Pad Prism to calculate EC50 values that were derived using a curve fitting analysis model for non-linear curve regression, sigmoidal dose response with variable slope formula. Data files were analyzed using FlowJo version 7.6.5.software, FSC-A vs VL1-A.
AGS67E Apoptosis:
Exponentially growing cells were seeded in a 48 well plate overnight and resuspended in Annexin V Pac Blue and Sytox-7AAdvanced (Life Technologies) as recommended by manufacturer. Following a 30 minute incubation, cells were acquired using an Attune cytometer with 405/VL-1 (Annexin V) and 488/BL-3 (Sytox-7AAdvanced) filter settings. Data files were analyzed using FlowJo version 7.6.5.software.
AGS67E Cell Line Xenograft Studies:
Five to six-week-old female CB17/SCID mice (Charles River) were maintained and used at Agensys' animal facility using IACUC approved protocols. Depending on the cell line, 1-10e6 cells were injected into the flanks of individual SCID mice and tumor volumes were allowed to reach 100-300 mm3. Animals and their tumors were size matched and randomized into treatment and control groups. Depending on the study, AGS67E and an isotype control ADC were dosed by intravenous bolus injection either at 0.25, 0.75, 1.5, or 3.0 mg/kg at BIW or QW frequencies and for a total of 2-4 doses. Tumor growth was monitored using caliper measurements every 3 to 4 days until the end of study. Tumor volume was calculated as width 
RESULTS
CD37 expression in normal and cancer tissues
CD37 expression was evaluated in normal PBMCs ( Figure 1A ) and normal solid tissues ( Figure   1B ) using flow cytometry and IHC respectively. Figure 1A shows strong staining for CD37 in CD20+ B cells. In comparison, CD56+, CD3+, CD14+ and CD66+ cells showed 11, 12, 32 and 28 fold less CD37 staining respectively. CD37 staining was not observed on CD61+ platelets.
To assess CD37 expression in normal solid tissues, 198 samples were tested representing 32 human tissues. Figure 1B , shows only those samples where CD37 expression was detected: lymph node, spleen, bone marrow, colon, small intestine, thymus and tonsil (skin was incorporated as a negative control). These are tissues where lymphocytes are known to reside and it is these lymphocytes that were shown to express CD37.
With respect to CD37 expression in cancer tissues, Figure 2A 
Novartis Cancer Cell Line Encyclopedia (19) for novel targets in AML, we discovered that some AML cell lines appeared to exhibit RNA expression of CD37. Since we did not expect this lymphoid marker to be expressed in myeloid cells, we sought to determine whether primary AML samples expressed CD37 at the protein level. Figure 2B Figure 3A) is a fully human anti-CD37 monoclonal IgG2 antibody conjugated to the potent microtubule-disrupting agent, MMAE, via reduced cysteines and the protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. The affinity (Ec50) and cytotoxicity (Ic50) of AGS67E to human B cells was 0.16 nM and 17 nM respectively ( Figure S1) and we have shown that upon binding to CD37 this ADC internalizes within 100 minutes as confirmed using flow cytometry ( Figure S2 ). We have also determined that the unconjugated antibody of AGS67E (AGS67C) did not exhibit anti-tumor efficacy ( Figure S3 ) nor did it induce ADCC in vitro ( Figure S4 ). Methods used for Figure S1 -S4 can be found in the supplementary data.
Mechanism of action of AGS67E
AGS67E (
In an effort to better characterize the in vitro mechanism of action of AGS67E, its ability to alter cell viability/proliferation, cell cycle progression and apoptosis was assessed. Table I summarizes the in vitro cytotoxicity of AGS67E in cell lines representing NHL, CLL and AML. With the exception of Rec-1, all NHL cell lines were responsive to AGS67E activity that ranged in I C 50 from ~0.04-20 nM. For CLL, JVM-3 cells were tested with a mean I C 50 of 0.50 nM. A mean I C 50 of ~0.1-5.7 nM was observed for 7 different AML cell lines. AGS67E was also not cytotoxic in an additional 9 AML cells lines. CD37 was expressed by all cell lines tested with the exception of MOLT-4 (ALL) cells which were used as a CD37 negative cell line control. Figure   3C shows examples of the survival curves for a subset of cell lines shown in Figure 3B .
In comparison to an isotype ADC control, AGS67E consistently altered cell cycle progression in CD37 positive cell lines representing NHL, CLL and AML while showing no appreciable change in the cell cycle of Hel92.1.7 AML cells ( Figure 3C and Table II) which had been shown not to be responsive to AGS67E cytotoxicity in vitro ( Figure 3B and Table I ). In each cell line (Mino, MV4-11 or JVM-3), AGS67E treatment resulted in a substantial increase in cells in the G2/M phase of the cell cycle while in turn leading to significant decreases in cells that resided in the G0/G1 or S phases prior to AGS67E treatment. Overall, the relative impact of AGS67E treatment on cell cycle progression appeared greater in the leukemia lines than in the Mino lymphoma cells. Further, the effect of AGS67E on the MV4-11 AML cell line was greater than on the JVM-3 CLL cell line. These observations did not correlate with relative doubling times of the cell lines. For reference, free MMAE payload, DMSO and no treatment groups were included in the analysis.
As was seen with the ability of AGS67E to induce cytotoxicity, the ability of AGS67E to induce apoptosis was also consistent across the Mino, MV4-11 and JVM-3 cell lines (Table III) 
Efficacy of AGS67E in NHL and CLL cell line xenografts
Since in vitro drug response assays do not always reflect the in vivo setting, we turned to xenografting. Table IV summarizes the efficacy of AGS67E in a variety of NHL, CLL and AML cell line xenografts. Although different dosing and schedules were used, efficacy was observed with every lymphoma xenograft, AGS67E appeared to show a greater absolute effect in the leukemic xenografts with 3/6 showing tumor stasis or complete regression and tumor free animals. However, 2/6 of the AML xenografts also showed tumor growth inhibition that was <50% and Hel.92.1.7 showed no anti-tumor activity following AGS67E treatment. As with in vitro activity of AGS67E, the levels of CD37 did not show a correlation with in vivo activity. Figure 4A shows 
Efficacy of AGS67E in patient-derived orthotopic AML xenografts
To determine whether AGS67E could inhibit orthotopic AML xenografts, we turned to patientderived samples. Figure 5A shows the experimental design to evaluate the ability of AGS67E to inhibit established and disseminated growth of patient-derived orthotopic AML xenografts. 
DISCUSSION
Within the context of antibody-based therapeutics, hematologic malignancies are frequently targeted. While Rituxan and CD20 targeting have paved the way in treating B-cell malignancies (7) (8) , resistance to Rituxan has led to the evaluation of other cell surface targets and a variety of non-antibody and antibody-based therapeutics (20) (21) (22) , one such target is CD37. Currently, three publically disclosed antibody therapeutics that target CD37 are in clinical development (11) (12) (13) . These include naked antibodies as well as a recently reported ADC (13) . Interestingly, all of these antibodies are human IgG1 isotypes with enhanced ADCC activity that has been reported, in addition to apoptosis induction, as integral to their mechanism of action.
Here, we introduce AGS67E, the first fully human anti-CD37 monoclonal IgG2κ antibody conjugated to the potent microtubule-disrupting agent, MMAE, via reduced cysteines and the protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl. We have shown that this ADC has high affinity for and rapidly internalizes CD37 and that it is cytotoxic, apoptotic and alters the cell cycle of cell lines representing NHL and CLL in vitro. We also showed that AGS67E inhibits growth of several xenografts representing NHL and CLL.
In contrast to the other reported anti-CD37 therapeutics, the unconjugated antibody component (AGS67C) of our ADC has not exhibited anti-tumor activity, nor has it demonstrated appreciable apoptotic or cytotoxic activity. AGS67C was selected for its ability to optimally and potently deliver the MMAE payload of AGS67E. Because AGS67C is a fully human IgG2, we observed very low ADCC activity in vitro using PBMCs, but demonstrated increased ADCC activity when the isotype of this antibody was switched to human IgG1. Since the pre-clinical potency of our agent is similar or superior to the reported pre-clinical efficacy of other CD37 antibodies in similar models of B cell malignancies (11-13), we postulated that adding ADCC and apoptosis inducing capability to the unconjugated antibody component of our ADC was unnecessary and further that it could prove to be a liability from a toxicology or pharmacokinetic perspective when the drug is eventually tested in humans.
Using the unconjugated antibody that makes up AGS67E as well as another anti-CD37 antibody, 9a73.1, we have also confirmed previously reported expression of CD37 in malignant B/T cells, normal B cells and in various PBMCs and in certain normal tissues where lymphocytes reside (1, 6) . For the first time, we report that CD37 is also expressed in T-cell lymphomas, AML and in AML CD34+CD38-stem cells while having minimal to no expression in normal CD34+CD38-stem cells. Moreover, we report that AGS67E potently inhibits AML cell line and patient-derived samples in vitro and in vivo using subcutaneous and orthotopic/disseminated models. These data support a potential new therapeutic avenue for AGS67E and possibly for existing and new CD37 targeted therapeutics.
Interestingly, during these studies, we found some intriguing differences upon AGS67E targeting of NHL, CLL and AML cell lines versus patient derived samples. First, while the absolute in vitro sensitivity of NHL, CLL and AML cell lines to AGS67E generally correlated with in vivo efficacy, there was not a direct rank order correlation between in vitro and in vivo efficacy nor was there a tight correlation with CD37 levels. Despite expressing significant CD37 levels, AGS67E was less efficacious is some cell lines and although not fully understood, may be attributable to inabilities of ADC internalization and/or processing as well as resistance. Second, the in vitro potency of AGS67E in AML cell lines was approximately an order of magnitude less than in NHL cell lines. Initially, we speculated that this was due to CD37 levels being approximately an order of magnitude lower in AML versus NHL cell lines and xenografts, but the in vivo potency in AML xenografts appeared greater than that of NHL xenografts, with tumor regressions and a higher incidence of tumor free mice observed. Third, in contrast to NHL and CLL cell lines, where nearly all were sensitive to AGS67E in vitro and in vivo, the sensitivity of AML cell lines to AGS67E in vitro (7/16) and is likely due to the genetic complexity and heterogeneity of AML as well as increased susceptibility of individual cell lines and xenografts to AGS67E and its microtubule disrupting payload. This possibility is also extended to the NHL and CLL cell lines in which CD37 was expressed but where efficacy was not observed. Interestingly, when we tested AGS67E in patient-derived AML samples in vivo, 4/4 samples were potently inhibited by AGS67E, thus indicating that there may be differences in the susceptibility of extensively passaged AML cell lines versus fresh patient-derived AML samples to the effects of AGS67E. In any case, further investigation will be needed to predict response and extent of response to AGS67E in AML as well as in NHL and CLL.
Taken together, the potent activity exhibited by AGS67E highlights its therapeutic potential in B/T-cell malignancies and in AML and supports its current clinical development. To our knowledge, this body of work is also the first demonstration that CD37 is well expressed in Tcell lymphomas and AML and that CD37 is a potential drug target in these diseases. Table II ) and apoptosis (Table III) 
